Quoin Gains FDA Fast Track for QRX003 in Peeling Skin Syndrome
ASHBURN, Va. — September 22, 2026 Quoin Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Fast...
regulatory milestone
Advertisement
CalciMedica Aligns With FDA on Auxora Phase 2b Trial
LA JOLLA, Calif., July 29, 2026 CalciMedica, Inc. has announced a significant regulatory milestone after reaching alignment with the...
Grünenthal Receives Dual FDA Designations for Tegacorat in DMD
AACHEN, Germany, July 8, 2026 Grünenthal has announced that the U.S. Food and Drug Administration (FDA) has granted both...
SK Life Science NDA for Cenobamate Suspension Accepted
PARAMUS, N.J., June 15, 2026 SK Life Science, Inc. has announced that the U.S. Food and Drug Administration (FDA)...
Kashiv BioSciences Moves Closer to Launching XOLAIR Biosimilar in Canada
PISCATAWAY, N.J., June 4, 2026 Kashiv BioSciences has announced a significant regulatory milestone with the validation and acceptance by...
Advertisements
Pharming’s Joenja Wins CHMP Nod for APDS in EU
LEIDEN, Netherlands, March 27, 2026 Pharming Group N.V. announced that the Committee for Medicinal Products for Human Use (CHMP)...
CHMP Endorses Monthly Elfabrio Dosing for Fabry Disease
PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 — Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the...
FDA Approves NEREUS™, First New Motion Sickness Drug in 40 Years
Washington, D.C. | December 30, 2025 — Vanda Pharmaceuticals Inc. has announced U.S. Food and Drug Administration (FDA) approval...
FDA Approves Addyi® for Postmenopausal Women With HSDD
RALEIGH, North Carolina — December 15, 2025 — Sprout Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA)...
Health Canada OKs Sephience™ for Phenylketonuria (PKU)
TORONTO, Dec. 10, 2025 — Health Canada has granted regulatory approval to Sephience™ (sepiapterin), an oral therapy developed by...
Advertisement
